Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 338

Document Document Title
WO/2022/165148A1
The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.  
WO/2022/145459A1
The present invention addresses the problem of providing a compound having Nrf2-activation action. Provided are: compounds represented by general formula (I), or compounds of the lower-polarity group among two groups of diastereomers in ...  
WO/2022/133480A1
The present invention provides AHR agonists, composites thereof, and methods of using the same.  
WO/2022/109363A1
The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts, thereof: Formula (Ia) which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprisi...  
WO/2022/076620A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated disea...  
WO/2022/076625A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...  
WO/2022/076622A2
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...  
WO/2022/076618A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...  
WO/2022/076621A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, i...  
WO/2022/076626A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...  
WO/2022/076624A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...  
WO/2022/064187A1
A compound of formula (I-1), or a pharmaceutically acceptable salt or hydrate thereof, formula (I-1) wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected fr...  
WO/2022/032284A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2022/008674A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2021/255257A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2021/239862A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2021/231737A1
The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and p...  
WO/2021/218896A1
The present disclosure relates to an ecteinascidin derivative, a preparation method therefor and a medical use thereof, in particular, to a compound represented by general formula (I), a medical use thereof and a preparation method there...  
WO/2021/211922A1
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.  
WO/2021/197295A1
The present disclosure relates to a crystalline form of a macrocyclic indole derivative and a preparation method therefor. In particular, the present disclosure relates to a crystalline form of a compound of formula (I) and a preparation...  
WO/2021/165370A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2021/160617A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating preventing or curing HBV infection and...  
WO/2021/126316A1
The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by ...  
WO/2021/108254A1
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.  
WO/2021/099580A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2021/099579A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2021/061898A1
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for trea...  
WO/2021/032591A1
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in...  
WO/2021/032588A1
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds ...  
WO/2021/002473A1
The invention addresses the problem of providing a compound having Nrf2-activation action. The invention is the compound represented by general formula (I), a salt thereof, or a solvate thereof. General formula (I): In the formula: R1a a...  
WO/2020/254471A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2020/234483A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/221272A1
The present disclosure relates to an indole macrocyclic derivative, a preparation method therefor and use thereof in medicine. Specifically, the present disclosure relates to an indole macrocyclic derivative represented by general formul...  
WO/2020/206080A1
Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.  
WO/2020/185606A1
Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in tr...  
WO/2020/167984A1
Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compoun...  
WO/2020/151738A1
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth in the specification. Also provided c...  
WO/2020/147802A1
Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are a...  
WO/2020/138015A1
The present invention provides: a novel compound that is useful for treating or preventing infections associated with viruses belonging to the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), and that has an anti-RSV...  
WO/2020/103864A1
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I f...  
WO/2020/105068A1
The present invention relates to an improved and industrially viable process for the preparation of Trabectedin. The present invention also relates to an improved and industrially viable process for the preparation of Trabectedin Interme...  
WO/2020/097577A1
The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.  
WO/2020/090636A1
Provided are: a compound having excellent semiconductor characteristics; a method for producing the compound; an intermediate of the compound; a method for producing the intermediate; and an organic semiconductor material and an organic ...  
WO/2020/063792A1
The present invention relates to an indole macrocyclic derivative, a preparation method therefor and an application thereof in medicine. Specifically, the present invention relates to an indole macrocyclic derivative represented by gener...  
WO/2020/050546A1
The present invention provides a compound represented by formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode, and an ...  
WO/2020/041169A2
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...  
WO/2020/030781A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/023560A1
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also de...  
WO/2020/016434A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2019/161078A1
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...  

Matches 1 - 50 out of 338